This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pexa-Vec/Icaritin FDC

Lee's Pharmaceutical Holdings Limited

Drug Names(s): pexastimogene devacirepvec, SNG-162, JX-594, TG6006, thymidine kinase-deleted vaccinia virus plus GM-CSF

Description: Pexa-Vec/Icaritin is a fixed dose combination of Pexa-Vec(pexastimogene devacirepvec) and Icaritin.

Deal Structure: Lee's and Shenogen
In August 2016, Lees Pharmaceutical and Shenogen Pharma Group announced a collaboration agreement to jointly develop and commercialize in China a combination product that is composed of their respective clinical compounds, Pexa-Vec and icaritin, for treatment of late stage cancers.

Partners: Shenogen Pharma Group

Pexa-Vec/Icaritin FDC News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug